Senate committee advances bill banning insurer 'white‑bagging' for physician‑administered drugs

The Mississippi Senate Insurance Committee on May 20 advanced Senate Bill 2712, a measure that would prohibit health insurers and pharmacy benefit managers (PBMs) from requiring that physician‑administered specialty medications be routed outside a treating facility for patient pickup or home delivery.

Senator Boyd, the bill’s author, told the committee the measure targets so‑called “white‑bagging” and “brown‑bagging” practices, in which insurers or PBMs require drugs be supplied by a specialty pharmacy rather than stocked by the treating provider. Boyd said the bill applies only to physician‑administered drugs and not to self‑administered maintenance medications.

“Patient safety concerns greatly when this happens,” Boyd said, citing risks to refrigerated (“cold‑chain”) drugs, potential tampering or contamination, delayed treatment start times and challenges with dosing adjustments when providers cannot directly procure medications. She said hospitals and physicians support the proposal.

Boyd walked the committee through the bill’s text, noting definitions and line references that specify covered persons, health insurance issuers, participating providers and PBMs, and that the measure would prohibit an insurer or PBM from refusing to authorize, approve or pay for covered physician‑administered drugs when those drugs are provided by a hospital. She said the bill would require provider agreements to make drug administration payable and require payment to providers at the rate in the applicable health insurance agreement.

A committee member questioned whether the bill creates exceptions when a hospital legitimately cannot obtain a specialty drug. Boyd responded that the bill would not bar legitimate procurement by providers, but would bar contract terms that require white‑bagging or force patients to carry physician‑administered medications from their home to the provider.

The bill sponsor also said the measure would be aligned with the state’s consumer protection framework, referring to the consumer protection act language in the bill text.

Motion and procedural action: a committee member moved “Title sufficient, due pass.” The motion carried and SB 2712 was reported from committee.

Why it matters: supporters said the bill protects patients from delayed or compromised treatment and reduces administrative and liability risks for providers; opponents or skeptics raised questions about operational exceptions when specialty supply is not locally available.

Next steps: the bill will be reported out of committee for further Senate consideration.